Equities analysts predict that Dexcom (NASDAQ:DXCM) will announce earnings of ($0.32) per share for the current fiscal quarter, according to Zacks Investment Research. Eleven analysts have provided estimates for Dexcom’s earnings, with the highest EPS estimate coming in at ($0.10) and the lowest estimate coming in at ($0.43). Dexcom reported earnings of ($0.49) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 34.7%. The business is scheduled to issue its next quarterly earnings results after the market closes on Wednesday, May 2nd.
According to Zacks, analysts expect that Dexcom will report full year earnings of ($0.56) per share for the current year, with EPS estimates ranging from ($0.81) to ($0.27). For the next year, analysts expect that the firm will report earnings of ($0.24) per share, with EPS estimates ranging from ($0.85) to $0.02. Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover Dexcom.
Dexcom (NASDAQ:DXCM) last issued its quarterly earnings results on Tuesday, February 27th. The medical device company reported $0.10 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.03 by $0.07. Dexcom had a negative return on equity of 13.99% and a negative net margin of 6.99%. The business had revenue of $221.00 million for the quarter, compared to analyst estimates of $217.82 million.
A number of equities research analysts have recently weighed in on the company. Northland Securities restated a “sell” rating and set a $40.00 price target on shares of Dexcom in a research note on Tuesday, January 16th. ValuEngine lowered Dexcom from a “hold” rating to a “sell” rating in a research note on Thursday, February 8th. Piper Jaffray set a $78.00 price target on Dexcom and gave the stock a “buy” rating in a research note on Friday, March 23rd. Oppenheimer set a $80.00 price target on Dexcom and gave the stock a “buy” rating in a research note on Thursday, March 29th. Finally, Zacks Investment Research upgraded Dexcom from a “sell” rating to a “hold” rating in a research report on Friday, March 16th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $67.38.
In other Dexcom news, insider Terrance H. Gregg sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $56.86, for a total value of $568,600.00. Following the completion of the transaction, the insider now directly owns 484,559 shares of the company’s stock, valued at $27,552,024.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Richard Doubleday sold 2,581 shares of the business’s stock in a transaction that occurred on Friday, March 23rd. The shares were sold at an average price of $68.44, for a total value of $176,643.64. Following the completion of the transaction, the executive vice president now directly owns 94,429 shares of the company’s stock, valued at $6,462,720.76. The disclosure for this sale can be found here. In the last quarter, insiders sold 35,854 shares of company stock worth $2,141,081. 1.70% of the stock is owned by insiders.
Large investors have recently made changes to their positions in the business. American International Group Inc. acquired a new position in Dexcom in the fourth quarter valued at approximately $116,000. Thompson Davis & CO. Inc. acquired a new position in Dexcom in the fourth quarter valued at approximately $137,000. Zions Bancorporation lifted its holdings in Dexcom by 36,222.2% in the third quarter. Zions Bancorporation now owns 3,269 shares of the medical device company’s stock valued at $160,000 after acquiring an additional 3,260 shares during the period. Marco Investment Management LLC acquired a new position in Dexcom in the fourth quarter valued at approximately $201,000. Finally, D.A. Davidson & CO. acquired a new position in Dexcom in the fourth quarter valued at approximately $208,000.
Shares of DXCM stock traded up $0.69 during trading hours on Monday, reaching $73.07. 683,257 shares of the company’s stock were exchanged, compared to its average volume of 1,286,691. Dexcom has a 1 year low of $42.62 and a 1 year high of $81.91. The firm has a market capitalization of $6,296.85, a price-to-earnings ratio of -125.98 and a beta of -0.02. The company has a debt-to-equity ratio of 0.78, a quick ratio of 5.04 and a current ratio of 5.36.
COPYRIGHT VIOLATION NOTICE: “-$0.32 Earnings Per Share Expected for Dexcom (DXCM) This Quarter” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/16/0-32-earnings-per-share-expected-for-dexcom-dxcm-this-quarter.html.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Get a free copy of the Zacks research report on Dexcom (DXCM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dexcom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dexcom and related companies with MarketBeat.com's FREE daily email newsletter.